Catalyst Pharmaceuticals logo
Catalyst Pharmaceuticals CPRX
$ 23.3 0.0%

Annual report 2025
added 02-25-2026

report update icon

Catalyst Pharmaceuticals Cash Flow 2011-2026 | CPRX

Annual Cash Flow Catalyst Pharmaceuticals

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Operating Cash Flow

209 M 240 M 144 M 116 M 60.4 M 45 M 34.6 M -26.1 M -13.7 M - - - -9.88 M -5.14 M -4.99 M

Depreciation & Amortization

375 K 397 K 316 K 141 K 192 K 92 K 55 K 38 K 45.7 K 43.4 K 34.5 K 26.6 K 22.5 K 10.9 K 42.8 K

Accounts Payables

11.2 M 16.6 M 14.8 M 3.98 M 2.77 M 4.26 M 4.12 M 2.34 M 1.95 M 933 K 1.79 M 1.81 M 851 K 1.37 M 264 K

Accounts Receivables

126 M 65.5 M 53.5 M 10.4 M 6.62 M 5.99 M 10.5 M - - - - - - - -

Total Inventories

37.2 M 19.5 M 15.6 M 6.8 M 7.87 M 4.65 M 1.96 M 56 K - - - - - - -

All numbers in USD currency

Quarterly Cash Flow Catalyst Pharmaceuticals

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Operating Cash Flow

- - 60 M - - - 31.9 M - - - 12.1 M - 76 M 34.7 M 8.48 M - 41.2 M 19.5 M 3.81 M - 31.9 M 20.5 M 7.21 M - 22.3 M 6.06 M -8.02 M - -17.8 M -10.8 M -6.08 M - -9.71 M -7.08 M - - - - - - - - - - - - - - - - -2.25 M - -3.55 M -2.45 M -1.3 M - -3.55 M -2.29 M -831 K

Depreciation & Amortization

- - 115 K - - - 86 K - - - 69 K - 106 K 71 K 34 K - 159 K 128 K 97 K - 73 K 43 K 14 K - 6.53 K 20.2 K 13.7 K - 9.29 K 8.18 K 8.02 K - 12.8 K 13 K 13 K - 9.48 K 8.76 K 13.2 K - 11.3 K 8.98 K 8.15 K - 7.24 K 6.08 K 5.28 K - 5.71 K 5.71 K 5.36 K - 8.24 K 5.51 K 2.8 K - 7.45 K 21 K 6.44 K

Accounts Payables

9.1 M 5.53 M 11.2 M 16.6 M 11.6 M 7.12 M 10.3 M 14.8 M 4.6 M 4.42 M 3.39 M 3.98 M 2.53 M 2.32 M 5.14 M 2.77 M 2.75 M 2.92 M 2.56 M 4.26 M 4.26 M 4.26 M 4.26 M 4.12 M 4.12 M 4.12 M 4.12 M 2.34 M 2.34 M 2.34 M 2.34 M 1.95 M 1.95 M 1.95 M 1.95 M 933 K 933 K 933 K 933 K 1.79 M 1.79 M 1.79 M 1.79 M 1.81 M 1.81 M 1.81 M 1.81 M 851 K 851 K 851 K 851 K 1.37 M 1.37 M 1.37 M 1.37 M 264 K 264 K 264 K 264 K

Accounts Receivables

106 M 65.9 M 71.3 M 65.5 M 58.3 M 57.2 M 60.5 M 53.5 M 48 M 42.8 M 33.4 M 10.4 M 9.34 M 9.59 M 10.6 M 6.62 M 6.62 M 6.29 M 5.6 M 5.99 M 5.99 M 5.99 M 5.99 M 10.5 M 10.5 M 10.5 M 10.5 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Inventories

28 M 18.6 M 19.8 M 19.5 M 20 M 18 M 20 M 15.6 M 9.04 M 10.8 M 10.3 M 6.8 M 7.13 M 7.85 M 7.83 M 7.87 M 6.95 M 7.1 M 4.39 M 4.65 M 4.65 M 4.65 M 4.65 M 1.96 M 1.96 M 1.96 M 1.96 M 56 K 56 K 56 K 56 K - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Cash Flow Statement is one of the three key financial reports of the company Catalyst Pharmaceuticals, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Biotechnology sector

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
AbCellera Biologics AbCellera Biologics
ABCL
$ 3.56 - $ 1.06 B canadaCanada
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
AC Immune SA AC Immune SA
ACIU
$ 3.13 - $ 229 M schweizSchweiz
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
ADC Therapeutics SA ADC Therapeutics SA
ADCT
$ 4.22 - $ 105 M schweizSchweiz
Aptorum Group Limited Aptorum Group Limited
APM
$ 0.79 0.01 % $ 4.31 M chinaChina
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
argenx SE argenx SE
ARGX
$ 703.3 - $ 25 B niderlandNiderland
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 231.03 2.23 % $ 5 B danmarkDanmark
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.61 - $ 8.69 B australiaAustralia
Atea Pharmaceuticals Atea Pharmaceuticals
AVIR
$ 6.05 - $ 493 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
$ 6.63 - $ 182 M israelIsrael
BioCardia BioCardia
BCDA
$ 1.27 - $ 26.9 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Athersys Athersys
ATHX
- 3.77 % $ 22.4 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Catalyst Biosciences Catalyst Biosciences
CBIO
$ 11.58 - $ 1.03 B usaUSA
Cerus Corporation Cerus Corporation
CERS
$ 1.8 6.51 % $ 343 M usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
$ 14.36 - $ 210 M usaUSA
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 90.54 - $ 27.2 B germanyGermany
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Burford Capital Limited Burford Capital Limited
BUR
$ 8.05 - $ 1.34 B britainBritain
AVEO Pharmaceuticals AVEO Pharmaceuticals
AVEO
- - $ 521 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
CNS Pharmaceuticals CNS Pharmaceuticals
CNSP
$ 2.45 0.41 % $ 936 K usaUSA
Aytu BioScience Aytu BioScience
AYTU
$ 2.64 - $ 16.6 M usaUSA
Cardiff Oncology Cardiff Oncology
CRDF
$ 1.9 - $ 127 M usaUSA
CorMedix CorMedix
CRMD
$ 6.54 - $ 471 K usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.51 - $ 385 M britainBritain